SEI Investments’s Fate Therapeutics FATE Stock Holding History

SEI Investments’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192K	Sell	70,980 -67,600	-49%	-$125K	﹤0.01%	3052
2026 Q1	$166K	Buy	138,580 +70,937	+105%	+$86.4K	﹤0.01%	3007
2025 Q4	$66.5K	Sell	67,643 -78	-0.1%	-$94	﹤0.01%	3054
2025 Q3	$85.3K	Hold	67,721	–	–	﹤0.01%	2736
2025 Q2	$75.9K	Sell	67,721 -122	-0.2%	-$142	﹤0.01%	2717
2025 Q1	$53.6K	Buy	+67,843	New	+$83.1K	﹤0.01%	2672
2024 Q1	–	Sell	-18,066	Closed	-$67.6K	–	2651
2023 Q4	$67.6K	Buy	+18,066	New	+$42.6K	﹤0.01%	2542
2022 Q4	–	Sell	-65,144	Closed	-$1.46M	–	2580
2022 Q3	$1.46M	Buy	65,144 +12,241	+23%	+$354K	﹤0.01%	1669
2022 Q2	$1.31M	Buy	+52,903	New	+$1.46M	﹤0.01%	1726
2021 Q4	–	Sell	-5,922	Closed	-$353K	–	2607
2021 Q3	$353K	Sell	5,922 -860	-13%	-$67.5K	﹤0.01%	2243
2021 Q2	$588K	Sell	6,782 -12,251	-64%	-$987K	﹤0.01%	2009
2021 Q1	$1.66M	Buy	19,033 +630	+3%	+$60.4K	﹤0.01%	1537
2020 Q4	$1.67M	Sell	18,403 -2,242	-11%	-$139K	﹤0.01%	1471
2020 Q3	$823K	Buy	20,645 +4,522	+28%	+$158K	﹤0.01%	1677
2020 Q2	$553K	Sell	16,123 -8,083	-33%	-$241K	﹤0.01%	1801
2020 Q1	$538K	Buy	+24,206	New	+$612K	﹤0.01%	1714
2019 Q1	–	Sell	-4,360	Closed	-$71K	–	2926
2018 Q4	$71K	Hold	4,360	–	–	﹤0.01%	2267
2018 Q3	$71K	Hold	4,360	–	–	﹤0.01%	2153
2018 Q2	$49K	Buy	+4,360	New	+$48K	﹤0.01%	2515

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SEI Investments's FATE Position: Q2 2026 in Review

SEI Investments reduced its Fate Therapeutics (FATE) stake by 49% in Q2 2026, selling an estimated $125K and leaving 70,980 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

SEI Investments first reported a position in FATE in Q2 2018 and has held it in 19 quarters since. The position peaked at $1.67M in Q4 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

SEI Investments held 70,980 shares of Fate Therapeutics worth $192K as of Q2 2026.
SEI Investments sold 67,600 Fate Therapeutics shares in Q2 2026, an estimated $125K.
Fate Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3052 holding.
SEI Investments first reported a position in Fate Therapeutics in Q2 2018 and has held it in 19 quarters since.
SEI Investments's Fate Therapeutics position peaked at $1.67M in Q4 2020.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.